Nasal-type natural killer (NK) cell lymphoma is an infrequent aggressive malignant disease with very poor prognosis. We aimed to explore the possible role of the transcription factor STAT3 in the pathophysiology of this malignancy, as it was involved in oncogenesis and chemoresistance. For this, we established and characterized a continuous interleukin 2-dependent NK cell line (MEC04) from a patient with a fatal nasal-type NK-cell lymphoma. Cells harbored poor cytotoxic activity against K562 cells, and spontaneously secreted interferon-c, interleukin-10 and vascular-endothelium growth factor in vitro. STAT3 was phosphorylated in Y705 dimerization residue in MEC04 cells and restricted to the nucleus. Y705 STAT3 phosphorylation involved JAK2, as exposure of cells to AG490 inhibitor inhibited Y705 STAT3 phosphorylation. By using recombinant transducible TAT-STAT3-b (b isoform), TAT-STAT3Y705F (a STAT3 protein mutated on Y705 residue, which prevents STAT3 dimerization) and peptides inhibiting specifically STAT3 dimerization, we inhibited STAT3 phosphorylation and cell growth, with cell death induction. Finally, STAT3 was phosphorylated in Y705 residue in the nuclei of lymphoma cells in eight/nine patients with nasal-type NK/T-cell lymphoma and in YT, another NK cell line. Our results suggest that STAT3 protein has a major role in the oncogenic process of nasal-type NK-cell lymphomas, and may represent a promising therapeutical target.
Introduction
Natural killer (NK)/T-cell lymphomas have been recently recognized as a distinct lymphoma subtype within the World Health Organization classification. 1, 2 Clinically, it is a highly aggressive disease that typically presents as destructive lesions localized in the nasal cavity, the nasopharynx, paranasal sinuses or palate, and shows a predilection for the Asians, Mexicans and South Americans. Nasal NK/T-cell lymphomas derive putatively from NK cells or more rarely from a subset of gd-or ab-cytotoxic T cells and show a striking association with Epstein-Barr virus (EBV). 3 This latter is shown by the presence of EBV genomes in the neoplastic cells using in situ hybridization (ISH) with probes directed against EBERs and a type 2 latency with variable expression of the latent membrane protein 1 (LMP-1) and absence of EBNA-2. 4 End-stage disease may also be accompanied by a leukemic phase and may involve other extranodal sites such as liver, spleen, bone marrow, central nervous system, lung or skin. Pathological features of nasal-type NK/T-cell lymphomas are typically characterized by prominent tissue necrosis, as a consequence of angiocentric growth pattern and vascular damage with angioinvasion of the wall of vessels by lymphoma cells, which show a high range of cytological appearance and frequent apoptotic figures. Nasal-type NK/Tcell lymphomas are commonly complicated by hemophagocytic syndrome, which generally heralds death. This disorder is characterized by a poor outcome with only 39 and 49% 5-year event-free survival and overall survival, respectively, because of chemoresistance. 5 Few putative oncogenic mechanisms were reported. These involve mutations of genes regulating apoptosis such as Fas and p53, [6] [7] [8] [9] [10] as well as expression of P-glycoproteins. 11 Moreover, a low expression level of the granzyme B protease inhibitor 9 was associated with a worse prognosis and cell dedifferentiation, suggesting a role for this protein in the pathophysiology of these malignancies. 5 However, the mechanisms involved in the pathogenesis and resistance to treatment still remain poorly understood, and the deep research for this special tumor has been hampered by its rarity and insufficient supply of the tumoral samples. 12 Indeed, only a very small number of bona fide NK leukemia-lymphoma cell lines have been described in detail [13] [14] [15] [16] (for review, see Drexler and Matsuo 17 ). STATs (Signal transducers and activators of transcription) are transcription factors usually activated in response to cytokines and growth factors. 18 Physiologic ligand-dependent activation of STAT regulatory cascades is usually associated with modulation of cell growth and differentiation. Accordingly, a constitutive activation of STAT proteins may result in malignant transformation. 19, 20 In particular, a large variety of neoplastic primary cells as well as tumor-derived cell lines from patients harbor constitutively activated STAT proteins, especially STAT3. 21 The oncogenic role of STAT3 was particularly well documented in anaplastic large cell lymphoma, a lymphoma also derived from cytotoxic cells. [22] [23] [24] STAT3 activation was shown to provide a growth advantage to cells, but also confers resistance to conventional chemotherapies that rely on apoptotic machinery to eliminate tumor cells. 25 In this work, we developed a continuous cell line from a patient with fatal disseminated nasal-type NK-cell lymphoma. The poor prognosis of this malignancy and its usual chemoresistance suggested us that the transcription factor STAT3 may have a role in the oncogenic process. We could show that STAT3 was involved in survival and proliferation of malignant cells. Moreover, biopsy samples obtained from nine patients with NK-cell lymphoma also harbored constitutive STAT3 activation in almost all cases. Altogether, our findings provide strong evidence that STAT3 plays a major role in the oncogenic mechanisms of this disease, and may represent a promising therapeutical target.
Materials and methods

Patient
A 48-year-old caucasian female patient with no past medical history was referred to our Department for recent fever with cytopenias and a 6-month lasting nasal obstruction resembling sinusitis. A computerized tomography showed a marked mucosal thickening with a filling of both maxillar sinuses and lytic bone destruction. A right maxillary sinus biopsy was consistent with the diagnosis of nasal-type NK/T-cell lymphoma according to the World Health Organization classification. Hemoglobin level was 9.6 g per 100 ml, white blood cell count was 19.1 Â 10 9 /l, including 17% circulating lymphoma cells and 17 Â 10 9 /l platelets. Marrow aspirate showed evidence of massive erythrophagocytosis in association with hyperferritinemia and hypertriglyceridemia (35 000 ng/ml and 7.2 mmol/l, respectively), consistent with the diagnosis of hemophagocytic syndrome. T-cell receptor loci were in germline configuration and EBV genome was found in neoplastic cells, resulting in a final diagnosis of nasal-type NK-cell lymphoma. Besides blood and marrow infiltration by malignant cells, lymphoma staging revealed liver, pancreas, gut and lung involvement. Quantification of circulating EBV DNA as assessed by LMP-1 DNA amplification disclosed a high viral load (5 Â 10 6 copies/ml). A chemotherapy including aracytine, etoposide and novantrone was performed with transient and partial efficacy. A salvage chemotherapy associating vincristine, methotrexate and L-asparaginase was undergone with no efficacy, and the patient died at day 10 of this treatment (and 3 months after the initial diagnosis) in a context of multiorgan failure because of Candida glabrata septicemia and disseminated Aspergillus fumigatus infection.
Samples
Parafin-embedded blocks of the tumor biopsies of the nasal lesion obtained at diagnosis and of the intestine at relapse were collected for histological review, immunohistochemical analysis and EBV studies. For assessment of phospho-STAT3 expression in nasal NK/T-cell lymphoma, tumor samples from nine other patients with nasal-type NK/T-cell lymphoma were retrieved from the file of the Departement of Pathology (Hô pital Henri Mondor, Créteil). Smooth muscle cells as well as endothelial cells were used as internal positive controls, whereas two cases of ALK þ anaplastic large cell lymphoma were used as external positive controls. For the construction of paraffin-embedded cell block, cells were at first resuspended in 100% ethanol, then transferred onto a filter paper for automated processing of a paraffin block. Phospho-STAT3 expression was also assessed in YT, an additional NK cell line, as well as in two cases of hepatosplenic T-cell lymphoma and in DERL-2 and DERL-7 cell lines derived from a patient with a hepatosplenic T-cell lymphoma.
Normal NK cells were obtained from the peripheral blood mononuclear cells (PBMCs) from six normal individuals. NK cells were sorted by negative selection using anti-CD3 and anti-CD19 antibodies (Pharmingen, San Diego, CA, USA). CD3
-and CD19 -cells were purified using a FACSVantage cytometer (Beckton-Dickinson, San Jose, CA, USA). The final purity of normal CD56
þ cells was 495%. Informed consent was obtained from the patient and normal individuals. The study was approved by the institutional review board at Hô pital Saint-Antoine (Paris).
Generation of MEC04 cell line
The cell line presented here was established according to earlier published guidelines. 26 PBMCs were isolated from the patient by density centrifugation of buffy coat through Ficoll-Hypaque (Nycomed Pharma AS, Oslo, Norway). Cells were cultured in RPMI 1640 supplemented with 2 mM L-glutamine and 10% heatinactivated human serum in the presence of recombinant interleukin-2 (rIL-2) (Laboratoires Chiron, Amsterdam, the Netherlands) 100 U/l.
In some experiments, rIL-2-starved malignant cells were incubated with AG490, PD98056 (at concentrations ranging from 5 to 50 mM) or with a cell permeable STAT3 phosphorylated blocking peptide used at a final concentration of 2 mM (Calbiochem, La Jolla, CA, USA). This latter contains a membrane translocating sequence, a set of hydrophobic amino acids for membrane permeability (sequence: PY*LKTK-AAVLLPVLLAAP). 27 Vehicle was 0.1% dimethyl sulfoxide for AG490 or PD98056. For STAT3-blocking peptide, a peptide with the same amino acid sequence, but not phosphorylated, was used as control (PYLKTK-AAVLLPVLLAAP) (Mimotopes, Clayton, Victoria, Australia) at the same concentration. The percentage of living cells was evaluated using the trypan blue dye exclusion assay.
Animals
Six-week-old male mice (NOD/SCID) were injected with MEC04 cells (10 Â 10 6 per mouse) intraperitoneally after a 3.5 Gy irradiation, and their outcome was compared with the normal counterparts. Ten mice were examined weekly until all injected animals died. Histopathological analysis was carried out in one diseased mouse. Malignant cells were stained with antibodies directed against granzyme B, Tia1, CD7 (Novocastra Reagents, Leica Microsystems GmbH, Heidelberg , Germany) (1:80), and by ISH with fluorescein-conjugated EBV (EBER 1 and 2) oligonucleotides (DakoCytomation, Glostrup, Denmark) complementary to nuclear RNA portions of the EBER 1 and 2 genes.
Cell staining and fluorescence-activated cell sorting (FACS) analysis
Rat monoclonal antibodies that recognize human hematopoietic cell-surface antigens were used to characterize phenotypically MEC04 cells, and were all purchased from Pharmingen. We used fluoro-isothiocyanate (FITC)-and phycoerythrin-conjugated antibodies directed to surface CD2, CD3 (sCD3), 
NK-cell cytolytic assay
MEC04 and NK92 NK cell lines cytotoxicity was evaluated against the major histocompatibility complex class I-deficient human erythroleukemia K562 cell line in a standard 4-h 51 Cr release assay, as described earlier. 28 
Enzyme-linked immunosorbent assay
Quantification of interferon (IF)-g, IL-10, vascular-endothelial growth factor (VEGF), transforming growth factor (TGF)-b and tumor necrosis factor (TNF)-a and -b in culture supernatant was carried out using an enzyme immunoassay kit (R&D System, Minneapolis, USA) after overnight rIL-2 deprivation. Supernatants of normal human NK cells grown in the same conditions were used as control.
Quantification of EBV DNA and detection of LMP-1 variant
Quantification of EBV-DNA was carried out as well from MEC04 cell line established from the PBMCs of the patient, as from culture supernatant using quantitative real-time PCR assay as described earlier. 29 Furthermore, LMP-1 gene variant was detected on the basis of overlapping PCR assay amplifying LMP-1 sequence. The assay used the designed primers as follows: forward 5 0 -ATGACATGGTAATGCCTAGAAGTAAAG-3 0 ; reverse 5 0 -ACAATTGATGGAAGAGGTTGAAAA-3 0 . PCR products were analyzed by electrophoresis in a 3% agarose gel containing 2 mg/ml ethidium bromide. A 231-bp length from B95-8 EBV strain is considered as wild-type LMP-1 gene after sequencing, whereas a deleted fragment is of lower length (that is, 201 bp).
Immunohistochemistry, immunocytochemistry and confocal microscopy
Immunohistochemistry and immunocytochemistry were performed as described earlier, 30 by using an anti-Y705 STAT3 antibody (Biolabs, Cell Signaling technology, Danvers, MA, USA) (dilution 1:50, antigen retrieval with 1 Â citrate buffer pH 6.0, incubation overnight at 41C). The detection of EBV infected cells was carried out using either immunohistochemistry with a monoclonal antibody to LMP-1 (CS1-4, DakoCytomation) or ISH with fluorescein-conjugated EBV (EBER1 and 2) oligonucleotides (DakoCytomation) complementary to nuclear RNA portions of the EBER 1 and 2 genes. The ISH procedure was carried out on deparaffinized tissue sections as reported earlier. 3 For confocal study, cells were cytospun on slides (5 Â 10 4 cells per slide) for 2 min at 180 g, fixed with cold methanol for 10 min and 4% paraformaldehyde for 20 min at room temperature, and then permeabilized with 0.2% Triton X-100 for 5 min at room temperature. The slips were washed three times with 1 Â PBS, and cells were blocked with 10% horse serum, 1% bovine serum albumin and 0.02% NaNO 3 in 1 Â PBS for 45 min at room temperature. Cells were incubated overnight with polyclonal anti-STAT3 primary antibody (1:100) (Biolabs, Cell Signaling technology) in 1 Â PBS and bovine serum albumin at 41C. After three washes, cells were incubated with second antibody labeled with phycoerythrin (1:200) for 1 h. Mounting was carried out using Vectashield medium (Vector Laboratories, Burlingame, CA, USA) including DAPI (4 0 ,6-diamino-2-phenyindole) fluorochrome for nuclei staining. Slides were examined using a laser confocal microscope (Leica Microsystems, Heidelberg GmbH, Heidelberg, Germany).
Western blotting and antibodies
Western blotting experiments were carried out as described earlier (Coppo et al., 2003) . Antibodies were purchased from Biolabs (anti-phospho-Y705 STAT3, anti-phospho-Ser727 STAT3, anti-STAT3, anti-phospho-Erk1/2 and anti-Erk1/2 antibodies), Santa Cruz Biotechnology, Santa Cruz, CA, USA (antiphospho-Y1007/Y1008 JAK2 antibody), Upstate Biotechnology New-York, USA (anti-phospho-Y694 STAT5 and anti-STAT5 antibodies) and DakoCytomation (anti-LMP-1 antibodies, CS1-4). They were diluted 1:1000 (anti-STAT3, anti-STAT5, antiErk1/2 and anti-LMP-1 antibodies) or 1:500 (anti-phospho-Y705 STAT3, anti-phospho-Ser727 STAT3, anti-phospho-JAK2 and anti-phospho-Erk1/2 antibodies).
Purification of TAT proteins
Purification of TAT proteins was carried out as described earlier (Harir et al.
31
). Briefly, BL21 (DE3) pLysS bacteria (Stratagene, Amsterdam, The Netherlands) expressing the TAT fusion proteins were grown in LB broth medium containing 50 mg/ml ampicillin and 34 mg/ml chloramphenicol at 371C. TAT-STAT3-b, TAT-STAT3 Y705F, and TAT-wild-type STAT5 protein expression was induced by the addition of 1 mM Isopropyl-beta-D-thiogalactopyranoside (IPTG) at 371C for 4 h. Cells were harvested and sonicated in buffer A (8 M urea, 20 mM N-2-Hydroxyethylpiperazine-N 0 -2-ethanesulfonic acid (HEPES) (pH ¼ 8.0) and 500 mM NaCl). Lysates were clarified by centrifugation at 15 600 g for 4 min at 41C. The supernatants containing the recombinant TAT fusion proteins were equilibrated in 12 mM imidazole and then applied to Ni-Nta agarose columns (Qiagen, Courtaboeuf, France). Columns were washed with six bed volumes of buffer B (4 M urea, 20 mM HEPES (pH ¼ 8.0), 500 mM NaCl and 12 mM imidazole). After washing, bound proteins were eluted with buffer B containing 250 mM imidazole. Eluates were dialyzed against PBS or 0.9% NaCl with four buffer changes overnight at 41C. The purity and concentration of TAT fusion proteins were assessed by Coomassie blue-stained SDSpolyacrylamide gel electrophoresis using standard concentrations of bovine serum albumin.
In vitro proliferation studies of cells transduced with TAT proteins MEC04 cells were incubated as triplicates in flat-bottom 24-well plates at a density of 2 Â 10 4 cells/well in RPMI 1640 medium with 10% FCS and 100 U/l rIL-2, and supplemented with the different TAT fusion proteins at the indicated concentration for 24 or 48 h. The percentage of living cells was evaluated using the trypan blue dye exclusion assay.
Quantitative RT-PCR analysis of Bcl-X L and c-myc mRNA transcripts
Total RNA was purified from MEC04 cell line transduced or not with TAT-STAT3-b and TAT-STAT3 Y705F by using Trizol reagent (Invitrogen, Carlsbad, CA, USA), followed by treatment with DNAse I (Invitrogen) to discard any contaminating DNA. First strand cDNA was synthesized from 2 mg of total RNA using the Superscript II reverse transcriptase (Invitrogen) with 200 ng of random hexamers. Real-time PCR was carried out using an ABI PRISM 7700 Sequence Detection System (PE Applied Biosystems, Foster City, CA, USA). C-myc, Bcl-X L and glyceraldehyde-3 0 -phosphate dehydrogenase transcripts copy numbers were detected by the first PCR cycle during real-time analysis in which the initiation of exponential cDNA template amplification exceeds background by 10-fold (the threshold cycle (C T )). Primer sequences are listed in Supplementary data (Supplementary Table S1 ). PCR were carried out in duplicate using the Taqman master mix (PE Applied Biosystems) with 10 ng of cDNA. Calibration curves were established to verify that PCR efficiencies were similar for target genes and glyceraldehyde-3 0 -phosphate deshydrogenase. The relative quantification of target gene products of MEC04 cell line transduced or not with TAT-STAT3-b and TAT-STAT3 Y705F was calculated by the 2 ÀDDct method. 32 Genes were considered to be upregulated when 2 ÀDDct was 41, and downregulated if o1.
Statistical analysis
For analysis of cell proliferation and mortality, values represent the mean ± s.d. for at least three separate experiments. The significance of differences between experimental variables was determined by the use of the Student's t-test, and P o0.05 was considered as significant.
Results
Morphological and phenotypic analysis of primary cells
The original lymphoma biopsies at presentation (nasal) and at relapse (stomach) showed a pleomorphic proliferation of medium to large-sized atypical lymphoid cells with numerous apoptotic figures (Figure 1a) , associated with an angiocentric growth pattern, angioinvasive features and areas of necrosis.
À /CD8 À and CD56 þ phenotype (Figure 1b ) with an activated cytotoxic (Tia1 þ ) profile and expression of LMP-1 (not shown). ISH with EBER 1 and 2 probes showed that most tumor cells were positive for EBV (Figure 1c) . These results were consistent with a diagnosis of nasal-type NK/T-cell lymphoma.
MEC04 NK cell line characteristics
The peripheral blood mononuclear cells obtained from the patient on diagnosis were cultured in the presence of rIL-2 in January 2004. A continuous cell line, named MEC04, could be maintained for more than 3 years. This cell line is available on request from the corresponding author. Cells remained IL-2-dependent and were mycoplasm free. Their doubling time was 20 h. Cells had large nuclei with abundant basophilic cytoplasm containing scarce azurophilic granules (Figure 2a) . T-cell receptor-g and immunoglobulin H (Framework region (Fr)1, Fr2 and Fr3]) loci were in the germinal conformation. Cytogenetical analysis disclosed a near tetraploid pattern with a complex formula with numerous numerical and structural chromosome changes as follows: 50-82, ÀXx4 [13] ,À3 [12] , add(3)(p?24) [3] , À4 [12] , À5 [12] , del(6)(q12) [2] , þ del(6)(q12) [11] , add(6)(q26) [11] , del(7)(p1?2p1?5) [9] , add(7)(p1?2) [7] , À7 [4] , À8, À8 [12] , À9 [3] , À9, À9 [10] , À10, À10 [13] , À11 [13] , add(11)(p11) [4] , þ add(11)(p11) [8] , add(11)(q22) [10] , þ add(11) (q22) [2] , À12 [9] , À13 [11] , À14 [3] , À15 [4] , À16, [3] , À17 [4] , À17, À17 [8] , add(18)(p11) Â 2 [13] , þ 20 [3] , þ mar1 [12] , þ 1-7mars [11] cp [13] . As some structural abnormalities are present in duplicate, they occurred before endoreduplication, probably as some numerical one, whereas some others obviously occurred as secondary events (Figure 2b ). Twelve abnormalities were systematically observed in 11-13 of the analyzed cells, which provides evidence for cell clonality. This finding also rules out a possible cross-contamination with another established cell line. The cell line was immunophenotyped three times within 2 years. Table 1 shows the last detailed immunophenotypical features of MEC04 cells performed at 2 years after the cell line establishment. Immunophenotyping of MEC04 cells was similar to that of primary leukemic cells, with the exception for CD94, in which case expression was lost. This peculiar phenotypic profile strongly suggested that MEC04 originates from the CD56 þ bright NK-cell population with regulatory functions. These cells normally comprise about 10% of circulating NK cells, and have the capacity to produce variable levels of cytokines, such as IF-g, IL-10, VEGF, TGF-b, IL-13 and granulocyte-monocyte growth factor. They also have a low natural cytotoxicity and express adhesion molecules such as CD62L (L-selectin). 33 To confirm this hypothesis, we tested the cytotoxic properties of MEC04 cells against K562 cells. We found that MEC04 cells were poorly cytotoxic against K562 cells when compared with the control NK92 cell line (Figure 2c) . Moreover, MEC04 cells spontaneously released very high amounts of IL-10, and to a lesser extent IF-g and VEGF in the culture supernatant as compared with normal NK cells ( Table 2) STAT3 in nasal-type NK/T-cell lymphoma oncogenesis P Coppo et al evidence that MEC04 cells correspond to the CD56 þ bright NKcell subset. 33 In situ hybridization with EBERs probes disclosed EBV genome in virtually all MEC04 cells (Figure 2d ). LMP-1 genome amplification by PCR carried out from MEC04 cells and on the culture supernatant found a unique wild-type LMP-1 band, consistent with a clonal origin of MEC04 cells (Figure 2e ). No LMP-1 deleted variant was detected in MEC04 cells or in the supernatant warranting the absence of dual variants. The virions detected in the culture supernatant were sensitive to DNAse (not shown), suggesting that MEC04 cell line released cell-free fragments of EBV DNA by cellular lysis. By western blot analysis, we could evidence that LMP-1 protein was expressed in MEC04 cells; the expression level was mild when compared with SNK6 cells (Figure 2f) .
When injected intraperitoneally (10 Â 10 6 ) to 10 NOD/SCID mice after a 3.5 Gy irradiation, MEC04 cells resulted in death in all animals within 4-9 weeks (Figure 2g) . In our experiments, we chose to analyze one diseased mouse at 7 weeks after injection. At autopsy, the mouse showed a massive infiltration of various organs (kidneys, peritoneum and bone marrow) by MEC04 cells, which were stained for granzyme B, Tia1, CD3, CD7 (Figure 2h ) and CD56 (not shown). None of these organs were found to display images suggesting hemophagocytic syndrome.
STAT3 is constitutively phosphorylated in MEC04 cell line. Involvement of JAK2 and MAP-Kinase/Erk pathway
The resistance to therapy as observed in our patient, as well as the high amounts of VEGF released spontaneously by malignant cells 34 suggested that STAT3 was a promising candidate protein to account for oncogenesis in nasal NK-cell lymphoma. We thus examined phospho-STAT3 expression in primary cells from a gastric biopsy. We found that STAT3 was constitutively phosphorylated in the Y705 dimerization residue and localized in the nuclei of malignant cells (Figure 3a) . Confocal microscopy analysis also confirmed that STAT3 was constitutively expressed in the nuclei of MEC04 cells (Figure 3b) . From these results, we assumed that constitutive STAT3 activation might be a yet-unrecognized target for intervention in nasal NK-cell lymphoma. Therefore, we studied this process in more detail.
As STAT3 is usually activated by JAK proteins, we first attempted to inhibit STAT3 by using AG490, a chemical compound that inhibits JAK proteins, especially JAK2. For this, we exposed MEC04 cells 24 and 48 h to the JAK2 inhibitor, AG490. in the absence of rIL-2, and the number of living cells was estimated by the trypan blue exclusion method. We found that AG490 led to a significant dose-dependent growth inhibition (Figure 4a) . By western blot analysis, JAK2 inhibition resulted in a decrease in the level of phospho-Y705 STAT3 in a dose-dependent manner. A dose-dependent decrease in phospho-Y1007/Y1008 JAK2 was also observed. Inhibition of JAK2 by AG490 also led to a dose-dependent inhibition of phospho-Ser727 STAT3 (Figure 4b ). To further explore the mechanisms involved in STAT3 phosphorylation, we asked whether MAP-Kinase/Erk1/2 pathway could be involved in Ser727 STAT3 phosphorylation. For this purpose, we exposed MEC04 cells for 24 h to PD98056, a specific MEK1 inhibitor, the immediate upstream protein involved in Erk1/2 activation. We found that the inhibition of MEK1 by PD98056 led to a decrease of Ser727 phosphorylation in a dosedependent manner (Figure 4c) . Comparable results were obtained by using UO126, a MEK1/2 inhibitor (not shown). These results suggest that in this model, JAK2 is dysregulated and leads to cell growth advantage by constitutive phosphorylation of Y705 STAT3, but also Ser727 through MAP-Kinase/Erk pathway. Table 2 Quantification of cytokines concentration in culture medium
Interferon-g (mg/ml) 0 (0) 47. Abbreviations: IL-2, interleukin-2; IL-10, interleukin-10; VEGF, vascular-endothelial growth factor. Concentrations ( ± s.e.) are given for 10 6 cells/ml and represent the mean of at least three independent experiments. Control was a natural killer (NK) cell population from a healthy donor. 
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We also attempted to assess whether STAT5, another STAT protein involved in oncogenesis, would be involved in this model. For this purpose, MEC04 cells were analyzed for STAT5 phosphorylation by western blot analysis after rIL-2 deprivation overnight. We found that constitutive STAT5 phosphorylation was only barely detectable in MEC04 cells (Figure 4d ).
Selective inhibition of constitutive activation of STAT3 induces growth inhibition and cell death of MEC04 cell line
To assess the oncogenic role of STAT3 in our cell line more accurately, we first selectively inhibited this molecule by overexpressing two distinct mutated forms of STAT3. The first one, STAT3-b, is an isoform of STAT3 which was reported to act as a dominant-negative form of this latter. 35 The second one bears a single point mutation on the tyrosine residue involved in the dimerization and the nuclear translocation of STAT3, which was changed to phenylalanine (Y705F) (Figure 5a ). STAT3Y705F has been earlier shown to block the activation of endogenous STAT3 in various cell types, possibly by titrating out receptor docking sites. 36 As we failed to inhibit STAT3 with STAT3Y705F by using retroviral infections with the murine stem cell virusbased retroviral MigR1 (MIGR-MSCV) vector, we generated recombinant TAT-STAT3-b and TAT-STAT3Y705F fusion proteins (Figure 5a ). The use of TAT fusion proteins was reported to be an efficient approach to transduce either cell lines or primary cells. 31 TAT-STAT3-b and TAT-STAT3Y705F proteins were purified and quantified as described in 'Materials and methods' and incubated (100 nM) with MEC04 cells for 24 and 48 h in the absence of rIL-2. The number of living cells and cell mortality was estimated (Figure 5b As an independent confirmation of the role of STAT3 in MEC04 cells oncogenesis, we also incubated these cells with a cell-permeable peptide that has been shown to block the effects of tyrosine-phosphorylated STAT3 27 by selectively preventing its binding to DNA. 27 Incubation of MEC04 cells with 2 mM of STAT3 inhibitor peptide for 24-48 h without rIL-2 resulted in a reduction of the cell number by almost 50% with a comparable increase in cell mortality (Supplementary Figure S1A) . By western blot analysis, we showed that exposure of MEC04 cells to the STAT3 inhibitor peptide for 48 h resulted in a decrease in Y705 STAT3 phosphorylation (Supplementary Figure S1B) .
Constitutive Y705 STAT3 phosphorylation in NK cell lines and in tumor cells from patients with nasal-type NK/T-cell lymphomas
To determine whether the potential oncogenic role of STAT3 observed in MEC04 cells can be extended to patients with nasaltype NK/T-cell lymphoma, we analyzed the expression of the phosphorylated form of STAT3 in YT (another NK cell line) and in nine other patients with associated nasal NK/T-cell lymphoma using an anti-phospho-Y705 STAT3 antibody. All these cases were positive for LMP and/or EBER (not shown). In eight of nine patients with interpretable results, the nuclei of the malignant cells were stained, providing evidence for a constitutive phosphorylation of Y705 STAT3 in these tumors ( Figure 6 and data not shown). The percentage of positive cells were variable from 5% to more than 50%, and the staining intensity was heterogeneous, from weak to strong nuclear immunoreactivity (Table 3) . STAT3 phosphorylation was also observed in YT cell line ( Figure 6 ). By contrast, no Y705 phosphorylation was evidenced in two hepatosplenic T-cell lymphoma cell lines (DERL-2 and DERL-7), neither in two biopsies from patients with hepatosplenic T-cell lymphoma (data not shown).
Discussion
We report herein a new human NK cell line termed MEC04, derived from a nasal-type NK/T-cell lymphoma. Besides clinical presentation, arguments for the NK cell origin of our cell line is the NK-cell phenotype (that is, negativity for typical B-and T-cell-lineage markers and positivity for CD56 and NKG2A markers), the germline configuration of T-cell receptor and immunoglobulin loci and the association of MEC04 cell line with EBV. Of note, this latter feature along with negativity for CD4 marker allowed us to rule out the diagnosis of plasmacytoid dendritic cell leukemia, initially considered as a blastic NKcell lymphoma, and now considered as the malignant counterpart of normal plasmacytoid dendritic cells. 37 Human NK cells are viewed as divided into two subsets on the basis of the level of expression of CD56 at their surface, that is, CD56 bright and CD56 dim , each with distinct properties. 33 Different results presented here are in agreement with the fact that MEC04 cells originally correspond to the CD56 bright NK-cell subset. First, their immunophenotype was typical of CD56 bright NK cells, that is, a bright positivity for CD56 and no expression of CD16, neither of classical NK receptors, apart from NKG2A, which was found strongly positive in all cells on diagnosis. Second, MEC04 cells were poorly cytotoxic, and third, they released spontaneously very high amounts of IF-g and IL-10, which are cytokines reported to be classically released by CD56 þ bright NK cells. It is interesting to note that the massive cytokines secretion may at least in part account for the clinical picture of the patient. Indeed, the high IF-g production may result in hemophagocytic syndrome, 38 whereas IL-10 may account for the wasting and the profoundly altered performance status. Of note, though MEC04 cells induced a fatal disease in mice, they could not reproduce a hemophagocytic syndrome in mice. This observation may be explained by the fact that IF-g has speciesspecific biological activities. 
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From the study of our cell line, we herein bring evidence for the role of STAT3 in nasal-type NK/T-cell lymphoma oncogenesis. We first found using the MEC04 immortalized cells derived from a patient with a fatal nasal NK-cell lymphoma at a leukemic stage that STAT3 was constitutively translocated in the nuclei of malignant cells. In addition, STAT3 was constitutively STAT3 in nasal-type NK/T-cell lymphoma oncogenesis P Coppo et al phosphorylated on Y705 and Ser727 residues despite rIL-2 starvation. We showed that the oncogenic role of STAT3 was specific as its inhibition by two distinct STAT3 proteins with dominant-negative effect resulted in a significant decrease in survival and proliferation of malignant cells. Similar results were obtained with STAT3 inhibitory peptides. On the opposite, STAT5 had apparently no role in oncogenesis in our model as rIL-2 starvation led to a complete inhibition of its phosphorylation. Of importance, we showed by immunochemistry a constitutively phosphorylated Y705 STAT3 in neoplastic cells of most primary nasal NK/T-cell lymphoma samples tested, as well as in YT, another NK cell line. These results indicate that the constitutive activation of STAT3 is widely involved in the pathogenesis of nasal NK/T-cell lymphoma. STAT3 is known to play a crucial role in regulating cell growth, survival, motility and cell transformation by regulating a large spectrum of proteins, such as myeloid cell leukemia sequence 1 (Mcl-1), survivin, cyclin D1, Bcl-X L and Myc. 25 One of the potential mechanisms implicated in STAT3 oncogenesis might be the overexpression of Bcl-X L , one of the most important survival factors expressed in constitutively activated STAT3-associated cancers. 19 Indeed, promoters of Bcl-X L , as well as myc harbor multiple STAT3-binding sites, named acute-phase response elements or APRE sequences. In our model, we found that inhibition of activated STAT3 resulted in the downregulation of Bcl-X L and c-myc expression, which suggests a role for these two target genes in resistance to apoptosis, cell cycling and treatment refractoriness in nasal NK/T-cell lymphomas.
In malignant cells, STAT3 may be activated through different signaling pathways. 40, 41 By the use of inhibitors, we found here that JAK2 protein is involved in the constitutive phosphorylation of both Y705 and Ser727 STAT3 residues, and that Ser727 STAT3 in nasal-type NK/T-cell lymphoma oncogenesis P Coppo et al STAT3 phosphorylation by JAK2 also involved MAP-Kinase/ Erk1/2 pathway. In the light of these findings, JAK2 may be suggested as an additional promising candidate for targeted therapies, though these results need further confirmation with a more specific inhibition of JAK2. The mechanisms leading to a dysregulation of JAK2/STAT3 pathway in our model remain to be defined. Interestingly, these former may involve STAT3 itself, as STAT3 was reported to induce the expression of DNMT1, a DNA-methyl transferase involved in the methylation of tumor suppressor genes such as SHIP-1, which is involved in the dephosphorylation of activated JAK and STAT3 proteins. 42, 43 Activated STAT3 was also reported to have the capacity to amplify the transcription of its own gene, by binding specific consensus sequences within the promoter of this latter. 44, 45 The high amounts of cytokine release by MEC04 cells may be an additional mechanism by which JAK2/STAT3 pathway is dysregulated in our model. Indeed, several tumor-associated factors including IL-10 and VEGF are activators of STAT3, [46] [47] [48] and may therefore be involved in sustained STAT3 activation through an autocrine and paracrine loop. Overall, these findings provide interesting evidences to suggest that dysregulated STAT3 may subsequently amplify and exacerbate its own oncogenic activity.
MEC04 cells were found to release wild-type LMP-1 genome in culture supernatants as well as in vivo, consistent with an earlier infection of the original NK cell by EBV, a characteristic feature of nasal-type NK/T-cell lymphomas.
2 PCR analysis from MEC04 cells showed a single wild-type LMP-1 genome band, which shows that our cell line is clonal. The relationship between EBV infection and sustained activation of STAT3 is questionable. It might be hypothesized that a physical interaction between the cytoplasmic signaling domain of LMP-1 and JAK2, as reported for JAK3, 49 could play a role. We attempted to co-immunoprecipitate LMP-1 and JAK2 in MEC04 cells, but we failed to provide evidence for such association (data not shown). However, intermediate proteins which may interact between LMP-1 and JAK2, such as TRAFs or TRADD, may also be involved. 50 Specific inhibition of LMP-1 would be of interest to assess the question whether LMP-1 is oncogenic in our system.
In conclusion, our work supports the first evidence that STAT3 has a major and selective role in the pathophysiology of nasaltype NK cell malignancies. The properties of MEC04 cells, as well as the pattern of cytokines they secrete, may explain the number of clinical features of nasal-type NK-cell lymphomas. Finally, STAT3 may account for the high resistance of malignant cells to chemotherapy, and specific therapies aimed at targeting STAT3 should be highly efficient in this disease. Further studies are now required to assess the possible involvement of additional signaling pathways, which may act in concert with STAT3 in the transforming process. The cell line we developed, STAT3 in nasal-type NK/T-cell lymphoma oncogenesis P Coppo et al as well as our model developed from mouse injected with MEC04 cells, may represent an interesting model to study the efficiency of pharmacological compounds in vitro and in vivo, and help to clarify the oncogenic role of EBV in such diseases.
